Perspectives
Drug Pipeline Quarterly Update: March 2020
New drugs, new indications and news of note.
March 20, 2020These quarterly pipeline wrap-ups include new molecular entity approvals, drugs with approvable status from the FDA, potential blockbuster drugs and the dates of expected FDA approval, names of top selling brand-name drugs with generic availability in the past 12 months and names of top selling brand-name drugs that have patents expiring soon.
Related news
Perspectives
April 23, 2024
Expert Clinical Network Insights: April 2024
A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance
Perspectives
April 23, 2024
April Fraud Focus – How to prioritize drug safety at home
While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…
Perspectives
April 19, 2024
AMCP 2024: Behind the Research with Prerak Parikh
Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars